{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"61.2","upperLimit":"80.6","value":"71.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"67"}],"units":"Participants"}],"description":"VGPR or better rate was defined as the percentage of participants who achieved VGPR or complete response (CR) (including stringent complete response \\[sCR\\]) according to the IMWG criteria during or after the study treatment. VGPR: Serum and urine component detectable by immunofixation but not on electrophoresis, or \\>= 90% reduction in serum M-protein plus urine M-protein level \\<100 mg/24 hour; CR: negative immunofixation on the serum and urine, Disappearance of any soft tissue plasmacytomas and \\<5% PCs in bone marrow; sCR: CR in addition to having a normal FLC ratio and an absence of clonal cells in bone marrow by immunohistochemistry, immunofluorescence, 2-4 color flow cytometry.","dispersionType":"90% Confidence Interval","groups":[{"description":"Participants received daratumumab 1800 milligrams (mg) as a subcutaneous (SC) injection on Days 1, 8 and 15 of Cycles 1 to 3 (each cycle of 21 days) and on Day 1 of Cycle 4; bortezomib 1.3 milligrams per square meter (mg/m\\^2) SC injection on Days 1, 4, 8 and 11 of Cycles 1 to 4; lenalidomide 25 mg orally on Day 1 through Day 14 of Cycles 1 to 4 and dexamethasone 20 mg orally or intravenously (IV) on Days 1, 2 ,8, 9, 15 and 16 of Cycle 1 to 4.","id":"OG000","title":"Daratumumab (D)+Bortezomib+Lenalidomide+Dexamethasone (D-VRd)"}],"paramType":"NUMBER","populationDescription":"All treated analysis set included all participants who have received at least 1 dose of study treatment. This primary outcome measure (OM) was planned to be analyzed for D-VRd cohort only.","reportingStatus":"POSTED","timeFrame":"Up to 2 years and 3 months","title":"D-VRd Cohort: Percentage of Participants With Very Good Partial Response (VGPR) or Better Response","type":"PRIMARY","unitOfMeasure":"percentage of participants"}